Juniper Networks Announces Cloud Metro Innovation to Drive Sustainable Business Growth for Service Providers
Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced the innovation that will power its vision and strategy for Cloud Metro – a new category of solutions for service providers, optimized for metro transformation and sustainable business growth. Traditional “retro” metro networks are device-centric and are buckling under the extreme scale, agility and experience demands that widespread digital transformation and the advent of 5G services are bringing.
Today’s announcement focuses on enabling sustainable business growth, with a series of high-performance networking systems, powered by AI-enabled, cloud-delivered automation, specifically designed to build next generation Cloud Metro infrastructure. These systems will deliver significantly-reduced natural resource consumption capabilities to help sustain the planet, improved tools and simplified working methods to help sustain over-pressured operations teams, along with embedded service assurance and security capabilities to optimize service experience, all while enabling service providers to sustain profitable business growth.
Juniper’s new Cloud Metro systems uniquely feature industry-leading energy-efficient, adaptive power designs as their foundational principle, enabling unused features and Packet Forwarding Engines (PFEs) to be automatically switched off when not in use. The removable modular power shelf design reduces e-waste and extends system lifetimes by accommodating up to 48 times bandwidth growth within the same chassis. It is certified as Titanium grade by CLEAResult® in its 80 Plus program, the first and only metro networking device power module to accomplish such a rating.
The future-proofed scale, capacity, performance and smart features of Juniper’s Cloud Metro portfolio replace the traditional 3-5 year ‘rip-and-replace’ network lifecycles with 7-12 year lifecycles. Pay-as-you-go models and a breadth of interface options allow service providers to flex their investment economically in line with demand.
Juniper’s advanced use of AI and cloud-delivered automation equips service providers to simplify day-to-day workflows, deploy services faster (with device onboarding taking just minutes instead of hours), reduce trouble tickets and accelerate time-to-service (and therefore revenue) restoration. This significantly improves productivity, empowering network engineers and operators to accomplish more, which is critical for employee satisfaction and retention.
The new solutions also deliver up to 71 percent lower Total Cost of Ownership (TCO) by leveraging the latest generation of silicon, industry-leading system design and AI-enabled Device Onboarding-as-a-Service. Zero Trust security is built-in rather than bolted-on, while active service assurance is embedded to deliver proactive service testing, monitoring and remediation.
Solution News Overview:
- Juniper Paragon™ Automation as a Service¹ is the industry’s only AI-enabled, cloud-delivered automation portfolio for metro networks, delivering immediate time-to-service value from months to minutes and reduced Mean Time to Know (MTTK) and Mean Time to Recovery (MTTR).
- Juniper AI-Enabled Device Onboarding-as-a-Service is the first-use case to be launched leveraging Juniper Paragon Automation as a Service, driving real business outcomes by significantly reducing device onboarding times.
- Juniper Networks™ ACX7000 Family² products are sustainable, high-performance systems leveraging unique design and adaptive power innovations that deliver up to 77 percent lower power consumption, up to 64 percent better space efficiencies and 4-7 years longer system lifetime than leading competitive products available today. The portfolio also delivers the industry’s fastest router line card, highest 400GE density and fabric capacity per slot, up to 21.6 Tbps with 54x400GE ports, ready for 800G and beyond.
- Juniper Paragon Active Assurance³ test agents are embedded in JUNOS® OS Evolved, available in all ACX7000 models. This turns the cloud metro network into a distributed sensor for assuring user experience proactively which removes the need for additional, standalone probe hardware to be deployed. Additionally, with the new capability of emulating 5G UE/gNB, service providers can now simulate traffic for both the control plane and user plane, ensuring each 5G network slice meets expected SLA.
- Zero Trust Security ⁴ principles and the threat detection, analysis and prevention fundamentals of Juniper’s Connected Security portfolio have been applied throughout the Juniper Cloud Metro solution. Unique cryptographic digital identities are implemented with the Trusted Platform Module (TPM 2.0) across the Cloud Metro IP services fabric, enabling device attestation and RFC-compliant secure zero-touch provisioning (sZTP). In addition, file encryption and MACsec are implemented to protect data at rest and data in transit. This holistic approach to trust is further enhanced by Paragon’s ability to automatically validate the security deployment and operation across a network of ACX7000 devices.
- Juniper Networks 400G ZR/ZR+ optics ⁵ co-developed to reduce service provider costs by consolidating IP and optical layers with coherent pluggable optics, which eliminates an entire layer of DWDM transponder terminals by integrating 400G ZR/ZR+ Digital Coherent Optics (DCO). These optics fully comply with industry specifications from OpenZR+ and OIF.
Supporting Quotes
“In a world of 'retro metros,' Juniper’s new Cloud Metro solution stands apart. Our cloud-delivered Paragon Automation-as-a-Service promises immediate productivity increases for service providers. Instead of building complex, time-consuming 'DIY' automation solutions, they are empowered to focus on assuring service experiences for their customers. By extending our proven AI solution to the service provider WAN, we can improve productivity for customer operations teams by dramatically reducing trouble tickets and increasing network availability. And our extended ACX7000 Family delivers the most secure, assured, scalable and intelligent Cloud Metro portfolio on the market. This is the answer to service provider needs for a sustainable future for their profits, their people and the planet.”
- Brendan Gibbs, Senior Vice President of Automated WAN Solutions, Juniper Networks
“Digital transformation is moving into its next phase which is all about transforming operational technology (OT) and driving the distributed delivery of new applications and use cases based on emerging technologies such as AI and AR. The metro edge is key to supporting the massive data, real-time performance and sustainability demands that this new era of OT transformation is bringing. This important industry shift requires the re-imagining and re-engineering of the metro network and Juniper is showing leadership here in its Cloud Metro portfolio. Service providers that want to deliver reliable, secure and high-performing services at the metro edge with a sustainable business model should pay close attention.”
- Caroline Chappell, Research Director, Cloud Practice, Analysys Mason
“Our metro connectivity services across more than 260 major cities around the world meet our customers’ need for secure, scalable and high-performance networking. We experience continuous demand for secure connectivity and expect to see double-digit traffic growth on our network, as we continue to provide the great experience our customers require. We’re long-term supporters of Juniper’s vision for high-performance, scalable IP networking and are excited to see the significant enhancements and innovation featured in their Cloud Metro portfolio that can bring more benefits for our customers in the future.”
- Don MacNeil, Chief Operating Officer, GTT Communications
“We are excited that the partnership between Broadcom and Juniper has delivered such a comprehensive portfolio of WAN routing platforms, all based on our leading Jericho and Qumran silicon. This announcement is especially compelling as it showcases Broadcom’s Jericho 2c+ silicon enabling a 50 percent increase to the industry’s highest-density 400G routing line card in a modular chassis. With market-leading 54 ports of 400G per slot at 21.6Tbps, this performance underscores the unmatched scalability and power efficiency of the product offering. We are thankful for our engineering teams.”
- Ram Velaga, Senior Vice President and General Manager, Core Switching Group, Broadcom
Solution Availability
¹AI-enabled Paragon Automation-as-a-Service – available 1H23
²ACX7000 Family:
- ACX7100-32C, ACX7100-48L, ACX7509 – available now
- ACX7024 – orderable now, available Q3’22
- ACX7908, ACX7348 – orderable 1H’23
³Juniper embedded Paragon Active Assurance – available 2H’22
⁴ Built-in zero trust security with SaaS-based network trust attestation – available 1H’23
⁵Juniper 400G ZR/ZR+ optics – orderable & available Q3’22
Additional Resources
Cloud Metro Solution Page
Blog: Cloud Metro: Reimagining Metro Networks for Sustainable Business Growth
Blog: Welcome to the Future of Network Automation: Juniper Paragon Automation-as-a-Service
Blog: Reimagining Metro Architectures for the Experience-First Era
Blog: Balancing Design Choices for Sustainable Growth: Juniper ACX7000 Family
ACX7000 Family Datasheet
Solution Brief: Juniper Cloud Metro as the Experience Sensor
Solution Brief: AI-Enabled Device Onboarding as a Service
Demo: Paragon Automation as a Service Device Onboarding
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
Statement of Product Direction
The information on this page may contain Juniper's development and plans for future products, features, or enhancements ("SOPD Information"). SOPD Information is subject to change at any time, without notice. Juniper provides no assurances, and assumes no responsibility, that future products, features, or enhancements will be introduced. In no event should any purchase decision be based upon reliance of timeframes or specifics outlined as part of SOPD Information, because Juniper may delay or never introduce the future products, features, or enhancements.
Any SOPD Information within, or referenced or obtained from, this website by any person does not give rise to any reliance claim, or any estoppel, against Juniper in connection with, or arising out of, any representations set forth in the SOPD Information. Juniper is not liable for any loss or damage (howsoever incurred) by any person in connection with, or arising out of, any representations set forth in the SOPD Information.
category-serviceprovider
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220701005027/en/
Contact information
Media Relations:
Penny Still
Juniper Networks
+44 (0) 1372 385 692
pstill@juniper.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
